Endotoxaemia in haemodialysis: A novel factor in erythropoetin resistance?

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Harrison, Laura E A ^a   Burton, James O ^a   Szeto, Cheuk Chun ^b   Li, Philip K T ^b   McIntyre, Christopher W ^a,c  

^a ROYAL DERBY HOSPITAL   (United Kingdom)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; ENDOTOXIN; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; INTERLEUKIN 6;

ADULT; ANTICOAGULATION; ARTICLE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ENDOTOXEMIA; FEMALE; HEART ARREST; HEMODIALYSIS; HUMAN; INFLAMMATION; KIDNEY FAILURE; MALE; MORTALITY; PREDICTION; SYSTOLIC BLOOD PRESSURE; ULTRAFILTRATION;

EID: 84863098317     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040209     Document Type: Article

References (41)

1. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, et al. (1986) Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2: 1175-1178.
2. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM, (2003) The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 63: 1908-1914.
3. Macdougall IC, Tomson CR, Steenkamp M, Ansell D, (2010) Relative risk of death in UK haemodialysis patients in relation to achieved haemoglobin from 1999 to 2005: an observational study using UK Renal Registry data incorporating 30,040 patient-years of follow-up. Nephrol Dial Transplant 25: 914-919.
4. Perlman RL, Finkelstein FO, Liu L, Roys E, Kiser M, et al. (2005) Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis 45: 658-666.
5. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, et al. (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032.
6. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, et al. (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098.
7. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, et al. (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084.
8. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, et al. (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590.
9. Badve SV, Hawley CM, Johnson DW, (2011) Is the problem with the vehicle or the destination? Does high-dose ESA or high haemoglobin contribute to poor outcomes in CKD? Nephrology (Carlton) 16: 144-153.
10. Stivelman JC, (1989) Resistance to recombinant human erythropoietin therapy: a real clinical entity? Semin Nephrol 9: 8-11.
11. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, et al. (2004) Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19: ii1-47.
12. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, et al. (2006) Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17: 1181-1191.
13. Drueke T, (2001) Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 16: 25-28.
14. Richardson D, (2002) Clinical factors influencing sensitivity and response to epoetin. Nephrol Dial Transplant 17: 53-59.
15. Anker SD, Egerer KR, Volk HD, Kox WJ, Poole-Wilson PA, et al. (1997) Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 79: 1426-1430.
16. Kotanko P, Carter M, Levin NW, (2006) Intestinal bacterial microflora-a potential source of chronic inflammation in patients with chronic kidney disease. Nephrol Dial Transplant 21: 2057-2060.
17. Charalambous BM, Stephens RC, Feavers IM, Montgomery HE, (2007) Role of bacterial endotoxin in chronic heart failure: the gut of the matter. Shock 28: 15-23.
18. Feng SY, Samarasinghe T, Phillips DJ, Alexiou T, Hollis JH, et al. (2010) Acute and chronic effects of endotoxin on cerebral circulation in lambs. Am J Physiol Regul Integr Comp Physiol 298: R760-766.
19. McIntyre CW, Harrison LE, Eldehni MT, Jefferies HJ, Szeto CC, et al. (2011) Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol 6: 133-141.
20. Gunnell J, Yeun JY, Depner TA, Kaysen GA, (1999) Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 33: 63-72.
21. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1365-1371.
22. John SG, Owen PJ, Harrison LE, Szeto CC, Lai KB, et al. (2010) The impact of antihypertensive drug therapy on endotoxemia in elderly patients with chronic kidney disease. Clin J Am Soc Nephrol 6: 2389-2394.
23. Szeto CC, Kwan BC, Chow KM, Lai KB, Chung KY, et al. (2008) Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin J Am Soc Nephrol 3: 431-436.
24. Lumsden AB, Henderson JM, Kutner MH, (1988) Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology 8: 232-236.
25. Maxwell A, Gaffin SL, Wells MT, (1986) Radiotherapy, endotoxaemia, and nausea. Lancet 1: 1148-1149.
26. Peschel T, Schonauer M, Thiele H, Anker SD, Schuler G, et al. (2003) Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. Eur J Heart Fail 5: 609-614.
27. Krack A, Sharma R, Figulla HR, Anker SD, (2005) The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J 26: 2368-2374.
28. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, et al. (2003) Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 42: 761-773.
29. Carrero JJ, Stenvinkel P, (2010) Inflammation in end-stage renal disease-what have we learned in 10 years? Semin Dial 23: 498-509.
30. Weiss G, Goodnough LT, (2005) Anemia of chronic disease. N Engl J Med 352: 1011-1023.
31. Brendt P, Horwat A, Schafer ST, Dreyer SC, Gothert J, et al. (2009) Lipopolysaccharide evokes resistance to erythropoiesis induced by the long-acting erythropoietin analogue darbepoetin alfa in rats. Anesth Analg 109: 705-711.
32. Raij L, Shapiro FL, Michael AF, (1973) Endotoxemia in febrile reactions during hemodialysis. Kidney Int 4: 57-60.
33. Molina M, Navarro MJ, Palacios ME, de Gracia MC, Garcia Hernandez MA, et al. (2007) [Importance of ultrapure dialysis liquid in response to the treatment of renal anaemia with darbepoetin in patients receiving haemodialysis]. Nefrologia 27: 196-201.
34. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY, (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305.
35. McIntyre CW, Burton JO, Selby NM, Leccisotti L, Korsheed S, et al. (2008) Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol 3: 19-26.
36. Burton JO, Jefferies HJ, Selby NM, McIntyre CW, (2009) Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol 4: 914-920.
37. Diebel L, Kozol R, Wilson RF, Mahajan S, Abu-Hamdan D, et al. (1993) Gastric intramucosal acidosis in patients with chronic kidney failure. Surgery 113: 520-526.
38. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S, (2001) Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 134: 629-636.
39. Jakob SM, Ruokonen E, Vuolteenaho O, Lampainen E, Takala J, (2001) Splanchnic perfusion during hemodialysis: evidence for marginal tissue perfusion. Crit Care Med 29: 1393-1398.
40. Khanna A, Rossman JE, Fung HL, Caty MG, (2001) Intestinal and hemodynamic impairment following mesenteric ischemia/reperfusion. J Surg Res 99: 114-119.
41. Chan CT, Floras JS, Miller JA, Richardson RM, Pierratos A, (2002) Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 61: 2235-2239.